期刊文献+

NK细胞杀伤人骨髓瘤RPMI8226细胞的活性及其可能的机制 被引量:3

Cytotoxicity of NK cells against RPMI 8226 cells and its possible mechanism
下载PDF
导出
摘要 目的:研究同种异体NK细胞对人骨髓瘤RPMI 8226细胞的杀伤活性及其可能的机制。方法:LDH释放法检测NK细胞对RPMI 8226细胞和人白血病K562细胞的杀伤活性,流式细胞术和RT-PCR法分别检测K562和RPMI 8226细胞中NKG2D配体和HLA-Ⅰ类分子的表达;阻断K562和RPMI 8226细胞中NKG2D配体的表达后,检测NK细胞的杀伤活性。结果:NK细胞对RPMI 8226靶细胞的杀伤活性明显低于对K562靶细胞的杀伤(P<0.01)。K562细胞高表达NKG2D配体,不表达HLA-Ⅰ类分子;RPMI 8226细胞低表达NKG2D配体,高表达HLA-Ⅰ类分子,其HLA基因型为A 01,66;B 58,58;Cw 03,06。阻断NKG2D配体后NK细胞杀伤K562细胞的活性明显降低(P<0.01),而杀伤RPMI 8226细胞的活性无明显改变;阻断HLA-Ⅰ类分子,NK细胞杀伤K562细胞的活性无变化,而杀伤RPMI 8226细胞的活性明显提高(P<0.01)。结论:NK细胞杀伤RPMI 8226细胞的活性较低,其机制与RPMI 8226细胞高表达HLA-Ⅰ类分子、低表达NKG2D配体有关。 Objective: To observe the cytotoxicity of allogenic natural killer(NK) cells against myeloma RPMI 8226 cells and its possible mechanism.Methods: Cytotoxicity of NK cells against RPMI8226 and K625 cells was analyzed by LDH releasing assay.The expressions of NKG2D ligands and HLA-Ⅰ molecule on K562 and RPMI 8226 cells were measured by flow cytometry and RT-PCR,respectively.In the blocking experiments,the target cells were treated by monoclonal antibodies against HLA-Ⅰ molecule and NKG2D ligands before cytotoxicity of NK cells were examined.Results: The cytotoxicity of NK cells against RPMI 8226 target cells was lower than that against K562 cells.K562 cells expressed high levels of NKG2D ligands and did not express HLA-Ⅰ;RPMI8226 cells expressed low levels of NKG2D ligands and high levels of HLA-Ⅰ.The HLA-Ⅰ genotypes of RPMI 8226 cells were A 01,66;B 58,58;and Cw 03,06.NKG2D ligand blocking experiments revealed that the cytotoxicity of NK cells against K562 cells was greatly inhibited,but that against RPMI 8226 cells was not affected.Conversely,the cytotoxicity of NK cells against RPMI 8226 cells was obviously improved,and that against K562 cells was not affected when HLA-Ⅰ molecule was shaded.Conclusion: Weak expressions of NKG2D ligands and high expression of HLA-Ⅰ molecule may contribute to the reduced cytotoxicity of NK cells against myeloma RPMI 8226 cells.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2011年第2期149-154,共6页 Chinese Journal of Cancer Biotherapy
基金 国家自然科学基金资助项目(No.0611042000)~~
关键词 自然杀伤细胞 自然杀伤细胞受体 骨髓瘤 HLA—I类分子 NKG2D配体 natural killer (NK) cell NK cell receptor myeloma HLA-I molecule NKG2D ligand
  • 相关文献

参考文献20

  • 1Barlogie B, Desikan R, Edddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients [J]. Blood, 2001, 98(2): 492-494.
  • 2Lee SR, Kim SJ, Park Y, et al. Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma [ J]. Korean J Hematol, 2010, 45 (3) : 183- 187.
  • 3Efebera YA, Qureshi SR, Cole SM, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma [ J ]. Biol Blood Marrow Transplant, 2010, 16 (8) : 1122-1129.
  • 4Fionda C, Soriani A, Malgarini G, et al. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation [J]. J Immunol, 2009, 183(7) : 4385-4394.
  • 5Ryosei N, Jeanette B, Andreas B, et al. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity [ J]. Blood, 2008, 112 ( 8 ) : 2563-2574.
  • 6Benitez AC, Dai Z, Mann HH, et al. Expression, signaling proficiency, and stimulatory function of the NKG2D lymphocyte receptor in human cancer cells [Jl. Proc Natl Acad Sci U S A, 2011, 108(10) : 4081-4086.
  • 7郑国强,王芳,郑捷,刘安军.NKG2D及其配体在肿瘤免疫中的研究进展[J].生物技术,2009,19(5):87-90. 被引量:8
  • 8Vivier E, Tomasello E, Paul P1. Lymphocyte activation via NKG2D: Towards a new paradigm in immune recognition [J].Curr Opin Immunol, 2002, 14 ( 3 ) : 3062-3111.
  • 9Fernandez-Messina L, Ashiru O, Aguera-Gonzalez S, et al. The human NKG2D ligand ULBP2 can be expressed at the cell surface with or without a GPI anchor and both forms can activate NK cells [J]. J Cell Sci, 2011, 124(3) : 321-327.
  • 10Friese MA, Platten M, Lutz SZ, et al. MICA/NKG2D-mediated immunogene therapy of experimental gliomas [ J 1. Cancer Res, 2003, 63 (24) : 8996-9006.

二级参考文献54

  • 1孙琳琳,刘利民,孙学科,周刚,赵金玲.MIC基因的研究进展[J].免疫学杂志,2006,22(z1):131-134. 被引量:6
  • 2狄岩,张明,姜达.肿瘤化疗多药耐药性的分子机制及其干预[J].临床荟萃,2005,20(8):476-478. 被引量:3
  • 3Garrity D, Call ME, Feng J, et al. The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure[J]. Proc Nail Acad Sd USA, 2005, 102:7641-7646.
  • 4Rabinovich B, Li J, Wolfson M, et al. NKG2D splice variants: a reexamination of adaptor molecule associations[J].Immunogenelics, 2006, 58:81 - 88.
  • 5Segovis CM, Sehoon RA, Dick C.I, et al. PI3K links NKG2D signaling to a Cff, L pathway involved in natural killer cell adhesion, polarity, and granule secretion[J]. J Immunol, 2009, 1, 182(11):6933-6942.
  • 6Choi BK, Kim YH, Kang WJ, et al. Mechanisms involved in synergistic anticancer immunity of anti - 4 - 1BB and anti - CD4 therapy[J]. Cancer Res, 2007, 67:8891-8899.
  • 7Allez M, Tieng V, Nakazawa A, et al. CD4+ NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions [J]. Gastroenterology, 2007, 132: 2346- 2358.
  • 8Guerra N, Tan YX, Joncker NT, et .,d. NKG2D - deficient mice are defective in tumor surveillance in models of spontaneous malignancy[J]. Immunity, 2008, 28:571-580.
  • 9Takada A, Yoshida S, Kajikawa M, et al. Two novel NKG2D ligands of the mouse H60 family with differential expression pattems and binding affinities to NKG2D[J]. J Immunol, 2008, 180: 1678- 1685.
  • 10Eagle RA, Flack G, Warford A. Cellular expression, trafficking, and function of two isofonns of human ULBPS/RAET1G[J]. PLoS ONE, 2009, 4 (2) : 1371 - 1384.

共引文献17

同被引文献40

  • 1Bae DS, Hwang YK, Lee JK . Importance of NKG2D-NKG2D ligands interaction for eytolytie activity of natural killer cell [ J ]. Cell Immunol, 2012, 276(1/2) : 122-127.
  • 2Pievani A, Borleri G, Pende D, et al. Dual-functional capability of CD3^+ CD56^+ CIK ceils, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity [ J ]. Blood, 2011, 118(12) : 3301-3310.
  • 3Morisaki T, Onishi H, Koya N, et al. Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer ceils in hepatocellular carcinoma via the NKG2D-MICA/B system [ J ]. Anticancer Res, 2011, 31(7) : 2505-2510.
  • 4Huang B, Sikorski R, Sampath P, et al. Modulation of NKG2D- ligand cell surface expression enhances immune cell therapy of cancer [J]. J Immunother, 2011, 34(3) : 289-296.
  • 5Franceschetti M, Pievani A, Borleri G, et al. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxie T-EMRA lymphocytes [ J ]. Exp Hematol, 2009, 37 (5) : 616- 628.
  • 6Linn YC, Lau SK, Liu BH, et al. Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell [ J]. Immunology, 2009, 126(3) : 423-435.
  • 7Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors [ J ]. Expert Opin Biol Ther, 2012, 12(6) : 673-684.
  • 8Kim JS, Park YS, Kim JY, et al. Inhibition of human pancreatic tumor growth by cytokine-induced killer cells in nude mouse xeno- graft model [J]. Immune Netw, 2012, 12(6) : 247-252.
  • 9Thanendrarajan S, Kim Y, Schmidt-Wolf I. New adoptive immunotherapy strategies for solid tumours with CIK cells [ J ]. Expert Opin Biol Ther, 2012, 12(5) : 565-572.
  • 10Laport GG, Sheehan K, Baker J, et al. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation [J]. Biol Blood Marrow Transplant, 2011, 17 ( 11 ) : 1679- 1687.

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部